The Antibiotic-Resistant Bacteria That Is Going to Kill 10 Million People a Year by 2050

Antimicrobial resistance already kills 1.27 million people annually. By 2050 it could kill 10 million. Here is the specific bacterial strains to worry about and what is being done.

The WHO's assessment of antimicrobial resistance as one of the greatest threats to global health is backed by mortality data whose trajectory is alarming: approximately 1.27 million deaths were directly caused by antibiotic-resistant bacterial infections in 2019 (the most recent year for which comprehensive global data is available), and an additional 4.95 million deaths had AMR as a contributing factor. The O'Neill Commission's projection that AMR could cause 10 million deaths annually by 2050 — overtaking cancer as a global killer — is based on trajectory extrapolation from these base figures.

The specific bacterial pathogens that WHO has identified as the highest global priority for new antibiotic development — the ESKAPE pathogens — include Enterococcus faecium, Staphylococcus aureus (MRSA), Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species. These pathogens share specific resistance mechanisms: the ability to acquire antibiotic resistance genes from other bacteria, to form biofilms that protect against antibiotics, and to activate efflux pumps that expel antibiotic molecules before they can reach their target.

The specific crisis in the antibiotic development pipeline: developing a new antibiotic is expensive (typically $1-1.5 billion), slow (10-15 years from discovery to approval), and commercially unattractive (new antibiotics are deliberately used sparingly to prevent resistance from developing, limiting commercial revenue). Several major pharmaceutical companies have exited antibiotic development entirely, and the small companies that remain frequently go bankrupt before their antibiotics reach patients — as happened with Achaogen (cefiderocol developer) and Melinta (several novel antibiotics).

The 2026 interventions addressing this: push mechanisms (public funding for antibiotic development, including the Antimicrobial Resistance Action Fund) and pull mechanisms (guaranteed market commitments that ensure antibiotic developers receive revenue independent of sales volume). The UK implemented a 'subscription model' for antibiotic reimbursement — paying an annual fee for access to specific antibiotics regardless of volume — that serves as a demonstration for broader adoption.